SCHEMBL5715091

SCHEMBL5715091

O=C(Oc1ccc(CCOc2cccnc2)cc1)N1CCN(c2ccccn2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 8/20 0.54
ALDH1A1 P00352 7/20 0.54
TSHR P16473 7/20 0.54
CYP3A4 P08684 4/20 0.54
SMN1; SMN2 Q16637 4/20 0.54
CYP1A2 P05177 4/20 0.54
CYP2C9 P11712 4/20 0.54
CYP2C19 P33261 4/20 0.54
MAPK1 P28482 3/20 0.54
KDM4E B2RXH2 3/20 0.52
KMT2A Q03164 2/20 0.52
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
HPGD P15428 3/20 0.50
NPSR1 Q6W5P4 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
SLC6A7 Q99884 1/20 0.49
CYP2D6 P10635 2/20 0.48
MEN1 O00255 1/20 0.46
GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714610 0.89 HSD17B10 (0.54) HSD17B10ALDH1A1TSHRCYP3A4SMN1; SMN2
SCHEMBL5714971 0.88 ME2 (0.48) HSD17B10ALDH1A1TSHRCYP3A4SMN1; SMN2
SCHEMBL5715387 0.88 ME2 (0.46) HSD17B10ALDH1A1TSHRCYP3A4SMN1; SMN2
SCHEMBL5714420 0.88 TRPA1 (0.49) CYP3A4SLC6A7DRD2DRD4DRD3
SCHEMBL5714554 0.87 DRD2 (0.42) HSD17B10ALDH1A1TSHRCYP3A4SMN1; SMN2
SCHEMBL5715298 0.87 SLC6A7 (0.48) HSD17B10ALDH1A1TSHRCYP3A4SMN1; SMN2
SCHEMBL5714805 0.87 SLC6A7 (0.44) HSD17B10ALDH1A1TSHRCYP3A4SMN1; SMN2
SCHEMBL5715158 0.86 HSD17B10 (0.55) HSD17B10ALDH1A1TSHRCYP3A4SMN1; SMN2
SCHEMBL5714516 0.85 SMN1; SMN2 (0.54) HSD17B10ALDH1A1CYP3A4SMN1; SMN2MAPK1
SCHEMBL5715368 0.85 KDM4E (0.50) ALDH1A1TSHRCYP3A4CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160819-A1 Substitued piperazine carbamates LIPE, PNLIP, LIPC HSD17B10 285/4885ALDH1A1 1021/4885TSHR 439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.